Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOXP3 AUMsilence ASO
- Development stage
- Preclinical
- Lead developer
- AUM BioTech
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- In Vitro (cell Culture Medium)
01
Overview
FOXP3 AUMsilence ASO is a next-generation antisense oligonucleotide (ASO) developed by AUM Biotech (AUM LifeTech) designed to target FOXP3 mRNA. The compound utilizes a 2'-deoxy-2'-fluoro-beta-D-arabinose (FANA) sugar modification and a phosphorothioate backbone, structured as a DNA segment flanked by FANA segments (a gapmer configuration). By employing RNA silencing to downregulate the expression of the FOXP3 transcription factor, the drug aims to alleviate the immunosuppressive activity of regulatory T cells (Tregs) within the tumor microenvironment. Preclinical studies have demonstrated significant reduction of FOXP3 mRNA levels in peripheral blood mononuclear cells (PBMC) and clinical samples from patients with lung cancer, mesothelioma, and melanoma, supporting its development as a potential cancer immunotherapy.
- Other names
- FANA antisense oligonucleotide targeting FOXP3FOXP3 AUMsilence ASOFOXP-3 AUMsilence ASOFOXP 3 AUMsilence ASOAUMsilence FOXP3 ASO
02
Targets
FOXP3 (Forkhead box protein P3)
Beyond the preview
Go deeper on FOXP3 AUMsilence ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOXP3 AUMsilence ASO.